Contineum Therapeutics Inc (CTNM)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$8.31-1.07%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Contineum Therapeutics Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	7.5M
EPS	—	-0.463
Annual ending 2026-12-31
Revenue	—	4.29M
EPS	—	-1.708
Annual ending 2027-12-31
Revenue	—	2.2M
EPS	—	-1.995

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Improve operating income	A supporting condition in Contineum Therapeutics Inc's published investment case. The stated target is operating losses reduce by at least 10% YoY.	Intact	operating losses do not improve or worsen in FY26	Operating income: $-17.428M FY2026-Q2; GAAP. Published target: operating losses reduce by at least 10% YoY. Target and observation units differ. Source published Jul 30, 2026-17,428,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: c05f8611-9abe-4458-8fbb-ccaa0b4ff7b2. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Achieve positive cash flow from operations	The company is focused on achieving positive cash flow from operations, currently at -$16.27M.	Broken	cash flow from operations remains negative over next 4 quarters	Cash from operations: $-11.501M FY2026-Q2; GAAP. Published target: >= $0 positive cash flow. Target period is not explicitly aligned with this observation. Source published Jul 30, 2026-11,501,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Reduce net income losses	Net income improved slightly to -$14.46M in 2026-Q1.	Improving	net income losses do not improve or worsen in FY26	Net income: $-15.154M FY2026-Q2; GAAP. Published target: net losses decrease by at least 10% YoY. Target and observation units differ. Source published Jul 30, 2026-15,154,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: c05f8611-9abe-4458-8fbb-ccaa0b4ff7b2. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-2.00

$-1.81 → $-2.00 · observed estimates

FY2027 revenueUnavailable

Unavailable → Unavailable · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-1.81	Unavailable	7 / 1
2026-07-25	$-1.81	Unavailable	7 / 1
2026-07-26	$-1.81	Unavailable	7 / 1
2026-07-27	$-1.81	Unavailable	7 / 1
2026-07-28	$-1.81	Unavailable	7 / 1
2026-07-29	$-1.81	Unavailable	7 / 1
2026-07-30	$-1.81	Unavailable	7 / 1
2026-07-31	$-1.81	Unavailable	7 / 1
2026-08-01	$-1.81	Unavailable	5 / 2
2026-08-02	$-1.82	$1,833,330	7 / 6
2026-08-03	$-1.82	$1,833,330	7 / 6
2026-08-04	$-1.82	Unavailable	5 / 4
2026-08-05	$-1.82	Unavailable	5 / 4
2026-08-06	$-1.82	$1,833,330	7 / 6
2026-08-07	$-1.82	Unavailable	5 / 4
2026-08-08	$-1.82	Unavailable	5 / 4
2026-08-09	$-1.82	$1,833,330	7 / 6
2026-08-10	$-1.82	$1,833,330	7 / 6
2026-08-11	$-1.82	$1,833,330	7 / 6
2026-08-12	$-1.82	Unavailable	5 / 4
2026-08-13	$-1.82	$1,833,330	7 / 6
2026-08-14	$-1.82	Unavailable	5 / 4
2026-08-15	$-1.82	Unavailable	5 / 4
2026-08-16	$-1.82	Unavailable	5 / 4
2026-08-17	$-1.82	Unavailable	5 / 4
2026-08-18	$-1.82	Unavailable	5 / 4
2026-08-19	$-1.82	Unavailable	5 / 4
2026-08-20	$-1.80	Unavailable	5 / 4
2026-08-21	$-1.80	Unavailable	5 / 4
2026-08-22	$-1.80	Unavailable	5 / 4
2026-08-23	$-1.80	Unavailable	5 / 4
2026-08-24	$-1.80	Unavailable	5 / 4
2026-08-25	$-1.80	Unavailable	5 / 4
2026-08-26	$-1.80	Unavailable	5 / 4
2026-08-27	$-1.80	Unavailable	5 / 4
2026-08-28	$-1.80	Unavailable	5 / 4
2026-08-29	$-1.80	Unavailable	5 / 4
2026-08-30	$-1.80	Unavailable	5 / 4
2026-08-31	$-1.80	Unavailable	5 / 4
2026-09-01	$-1.80	Unavailable	5 / 4
2026-09-02	$-1.80	Unavailable	5 / 4
2026-09-03	$-1.80	Unavailable	5 / 4
2026-09-04	$-1.80	Unavailable	5 / 4
2026-09-05	$-1.80	Unavailable	5 / 4
2026-09-06	$-1.80	Unavailable	5 / 4
2026-09-07	$-1.80	Unavailable	5 / 4
2026-09-08	$-1.80	Unavailable	5 / 4
2026-09-09	$-1.80	Unavailable	5 / 4
2026-09-10	$-1.80	Unavailable	5 / 4
2026-09-11	$-1.80	Unavailable	5 / 4
2026-09-12	$-1.80	Unavailable	5 / 4
2026-09-13	$-1.80	Unavailable	5 / 4
2026-09-14	$-1.80	Unavailable	5 / 4
2026-09-15	$-1.80	Unavailable	5 / 4
2026-09-16	$-1.84	Unavailable	5 / 4
2026-09-17	$-1.84	Unavailable	5 / 4
2026-09-18	$-1.84	Unavailable	5 / 4
2026-09-19	$-1.84	Unavailable	5 / 4
2026-09-20	$-1.84	Unavailable	5 / 4
2026-09-21	$-1.84	Unavailable	5 / 4
2026-09-22	$-1.94	Unavailable	5 / 4
2026-09-23	$-1.94	Unavailable	5 / 4
2026-09-24	$-1.94	Unavailable	5 / 4
2026-09-25	$-2.00	Unavailable	5 / 4
2026-09-26	$-1.99	Unavailable	5 / 4
2026-09-27	$-1.99	Unavailable	5 / 4
2026-09-28	$-1.99	Unavailable	5 / 4
2026-09-29	$-1.99	Unavailable	5 / 4
2026-09-30	$-1.99	Unavailable	5 / 4
2026-10-01	$-1.99	Unavailable	5 / 4
2026-10-02	$-1.99	Unavailable	5 / 4
2026-10-03	$-1.99	Unavailable	5 / 4
2026-10-04	$-1.99	Unavailable	5 / 4
2026-10-05	$-1.99	Unavailable	5 / 4
2026-10-06	$-1.99	Unavailable	5 / 4
2026-10-07	$-1.99	Unavailable	5 / 4
2026-10-08	$-1.99	Unavailable	5 / 4
2026-10-09	$-1.99	Unavailable	5 / 4
2026-10-10	$-1.99	Unavailable	5 / 4
2026-10-11	$-1.99	Unavailable	5 / 4
2026-10-12	$-1.99	Unavailable	5 / 4
2026-10-13	$-1.99	Unavailable	5 / 4
2026-10-14	$-1.99	Unavailable	5 / 4
2026-10-15	$-2.00	Unavailable	5 / 4
2026-10-16	$-2.00	Unavailable	5 / 4
2026-10-17	$-2.00	Unavailable	5 / 4
2026-10-18	$-2.00	Unavailable	5 / 4
2026-10-19	$-2.00	Unavailable	5 / 4
2026-10-20	$-2.00	Unavailable	5 / 4
2026-10-21	$-2.00	Unavailable	5 / 4
2026-10-22	$-2.00	Unavailable	5 / 4
2026-10-23	$-2.00	Unavailable	5 / 4
2026-10-24	$-2.00	Unavailable	5 / 4

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	6	1
2026-06-01	6	1
2026-07-01	7	1
2026-08-01	7	1
2026-09-01	7	1
2026-10-01	7	2

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 7 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell

0 upgrades1 downgrades2 maintains

Recent actions · Sep 25–Oct 24 · 3 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Stifel NicolausSep 30

$28.00New observation · no comparable prior

Morgan StanleySep 27 · prior May 14

$16.00 → $17.00+6.3%

$0$15.40$30.80

1 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Improve operating incomeOperating income: $-17.428M
Achieve positive cash flow from operationsPublished status: Broken
Reduce net income lossesNet income: $-15.154M

Next proof point

Oct 29, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.5%Typical daily move · historical

Downside history

-59.7%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Contineum Therapeutics Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

CTNM is a speculative clinical-development business, not an established earnings compounder. The long-term thesis is in a watch state: management has made progress on stated priorities, but confidence in the overall evidence is low and risk has recently risen.

What's priced into Contineum Therapeutics Inc

The snapshot does not provide a valuation measure or a clear account of market expectations, so whether CTNM looks cheap or expensive versus peers cannot be assessed. No fragility gates fired, but that does not resolve the gap between clinical progress and a business that remains loss-making.

What the fundamentals likely do

Near term, the next results carry meaningful execution risk: the snapshot flags a high-miss-rate industry and a 40% miss probability, while recent performance remains weak relative to its industry cohort. Over the multi-year view, enrollment in the Phase 2 IPF trial and positive early chronic-pain data support continued development, while cash runway through mid-2029 provides time; losses and high operating costs remain unresolved.

What Contineum Therapeutics Inc hinges on

The thesis hinges on continued clinical progress, reduced losses, and management maintaining its stated cash discipline. A guidance cut or further weakening in jobs data would add pressure, while stronger results and guidance from sector peers could support the healthcare backdrop.